Literature DB >> 29996196

[Diagnostic application of serum GP73 and the relevant mechanism in the diagnosis of liver cirrhosis].

F M Lu1, Y Zhang.   

Abstract

Liver cirrhosis is the end-stage change of chronic liver diseases with various causative factors. The accurate diagnosis of liver cirrhosis in an early stage is very important for the timely treatment and prognosis of patients. A liver biopsy test is the gold standard for the diagnosis of liver cirrhosis; but its use is limited in clinical practices due to its invasive nature. The conventional non-invasive measures (APRI, FIB-4 and LSM) for diagnosis of liver cirrhosis could not fulfill the needs. Therefore, finding a new serological marker of liver cirrhosis has become a research hotspot. Based on literature review and our own results, we suggest that serum GP73 as the most potential serum marker for liver cirrhosis diagnosis. This review briefly introduces the application of serum GP73 in the diagnosis of liver cirrhosis and the potential mechanism relevant to its involvement in the development of liver cirrhosis.

Entities:  

Keywords:  Diagnosis; Golgi protein 73; Hepatitis; Liver cirrhosis; Liver regeneration

Mesh:

Substances:

Year:  2018        PMID: 29996196     DOI: 10.3760/cma.j.issn.1007-3418.2018.05.001

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  2 in total

1.  Plasma Golgi protein 73 levels predict prognosis of HCV-related hepatic fibrosis.

Authors:  Lingdi Liu; Zaid Al-Dhamin; Xiwei Yuan; Luyao Cui; Yang Yang; Wen Zhao; Ying Zhang; Na Fu; Yuemin Nan
Journal:  Histol Histopathol       Date:  2020-10-14       Impact factor: 2.303

2.  Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels.

Authors:  Kenneth I Zheng; Wen-Yue Liu; Xiao-Yan Pan; Hong-Lei Ma; Pei-Wu Zhu; Xi-Xi Wu; Giovanni Targher; Christopher Byrne; Xiao-Dong Wang; Yong-Ping Chen; Fengmin Lu; Ming-Hua Zheng
Journal:  BMJ Open Diabetes Res Care       Date:  2020-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.